Ventricular hypertrophy abrogates intralipid-induced cardioprotection by alteration of reperfusion injury salvage kinase/glycogen synthase kinase 3β signal

Shock

Volumn 41, Issue 5, 2013, Pages 435-442

  Ma, Lei Lei ^a   Ge, Hong Wei ^b,c   Kong, Fei Juan ^b   Qian, Ling Bo ^d   Hu, Bang Chuan ^a   Li, Qian ^a   Xu, Liang ^a   Liu, Jing Quan ^a   Xu, Yun Xiang ^a   Sun, Ren Hua ^a  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY SHOUGANG HOSPITAL   (China)

^d ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cardiac hypertrophy; Cardioprotection; GSK3 ; Intralipid; Preconditioning

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; GLYCOGEN SYNTHASE KINASE 3BETA; INTRALIPID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOTRANSFERASE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; REPERFUSION INJURY SALVAGE KINASE; UNCLASSIFIED DRUG; WORTMANNIN; EMULSION; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; PHOSPHOLIPID; SOYBEAN OIL; SOYBEAN OIL, PHOSPHOLIPID EMULSION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; APOPTOSIS; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION SIZE; HEART PROTECTION; HEART RATE; HEART VENTRICLE HYPERTROPHY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; EMULSION; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; THERAPEUTIC USE;

ANIMALS; EMULSIONS; GLYCOGEN SYNTHASE KINASE 3; HYPERTROPHY, LEFT VENTRICULAR; MALE; MAP KINASE SIGNALING SYSTEM; MYOCARDIAL REPERFUSION INJURY; PHOSPHOLIPIDS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SOYBEAN OIL;

EID: 84925936597     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000130     Document Type: Conference Paper

References (34)

1. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349(9064): 1498-1504, 1997.
2. Murphy E, Steenbergen C: Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 88(2):581-609, 2008.
3. Heusch G: Cardioprotection: chances and challenges of its translation to the clinic. Lancet 381(9861):166-175, 2013.
4. Ma LL, Zhang FJ, Qian LB, Kong FJ, Sun JF, Zhou C, Peng YN, Xu HJ, Wang WN, Wen CY, et al.: Hypercholesterolemia blocked sevoflurane-induced cardioprotection against ischemia-reperfusion injury by alteration of the MG53/RISK/GSK3β signaling. Int J Cardiol 168(4):3671-3678, 2013.
5. Rahman S, Li J, Bopassa JC, Umar S, Iorga A, Partownavid P, Eghbali M: Phosphorylation of GSK-3β mediates intralipid-induced cardioprotection against ischemia/reperfusion injury. Anesthesiology 115 (2):242-253, 2011.
6. Li J, Iorga A, Sharma S, Youn JY, Partow-Navid R, Umar S, Cai H, Rahman S, Eghbali M: Intralipid, a clinically safe compound, protects the heart against ischemia-reperfusion injury more efficiently than cyclosporine-A. Anesthesiology 117(4):836-846, 2012.
7. Liu SL, Wang Y, Wang RR, Chai YF, Wu W, Huang H, Liu J: Protective effect of intralipid on myocardial ischemia/reperfusion injury in isolated rat heart. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 20(4):227-230, 2008.
8. Lecour S: Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? J Mol Cell Cardiol 47(1):32-40, 2009.
9. Juhaszova M, Zorov DB, Yaniv Y, Nuss HB, Wang S, Sollott SJ: Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res 104(11):1240-1252, 2009.
10. Wu QL, Shen T, Shao LL, Ma H, Wang JK: Ischemic postconditioning mediates cardioprotection via PI3K/GSK-3β/β-catenin signaling pathway in ischemic rat myocardium. Shock 38(2):165-169, 2012.
11. Gustafsson AB, Gottlieb RA: Bcl-2 family members and apoptosis, taken to heart. Am J Physiol Cell Physiol 292(1):C45-C51, 2007.
12. Das S, Wong R, Rajapakse N, Murphy E, Steenbergen C: Glycogen synthase kinase 3 inhibition slows mitochondrial adenine nucleotide transport and regulates voltage-dependent anion channel phosphorylation. Circ Res 103(9):983-991, 2008.
13. Ferdinandy P, Schulz R, Baxter GF: Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59(4):418-458, 2007.
14. Vakili BA, Okin PM, Devereux RB: Prognostic implications of left ventricular hypertrophy. Am Heart J 141(3):334-341, 2001.
15. Vogt M, Motz W, Scheler S, Strauer BE: Disorders of coronary microcirculation and arrhythmias in systemic arterial hypertension. Am J Cardiol 65(14): 45G-50G, 1990.
16. Ma LL, Zhang FJ, Kong FJ, Qian LB, Ma H, Wang JA, Yan M: Hypertrophied myocardium is refractory to sevoflurane-induced protection with alteration of reperfusion injury salvage kinase/glycogen synthase kinase 3β signals. Shock 40(3):217-221, 2013.
17. Zheng Z, Yang M, Zhang F, Yu J, Wang J, Ma L, Zhong Y, Qian L, Chen G, Yu L, et al.: Gender-related difference of sevoflurane postconditioning in isolated rat hearts: focus on phosphatidylinositol-3-kinase/Akt signaling. J Surg Res 170(1):e3-e9, 2011.
18. Yang C, Talukder MA, Varadharaj S, Velayutham M, Zweier JL: Early ischaemic preconditioning requires Akt-and PKA-mediated activation of eNOS via ser-ine1176 phosphorylation. Cardiovasc Res 97(1):33-43, 2013.
19. Wynne AM, Mocanu MM, Yellon DM: Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPK. J Cardiovasc Pharmacol 46(6):817-822, 2005.
20. Bell RM, Yellon DM: Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol 35(2):185-193, 2003.
21. Hu Y, Chen X, Pan TT, Neo KL, Lee SW, Khin ES, Moore PK, Bian JS: Cardioprotection induced by hydrogen sulfide preconditioning involves activation of ERK and PI3K/Akt pathways. Pflugers Arch 455(4):607-616, 2008.
22. Park SS, Zhao H, Mueller RA, Xu Z: Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3beta. J Mol Cell Cardiol 40(5):708-716, 2006.
23. Perlini S, Palladini G, Ferrero I, Tozzi R, Fallarini S, Facoetti A, Nano R, Clari F, Busca G, Fogari R, et al.: Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension 46(5):1213-1218, 2005.
24. Bell RM, Mocanu MM, Yellon DM: Retrograde heart perfusion: the Langendorff technique of isolated heart perfusion. J Mol Cell Cardiol 50(6):940-950, 2011.
25. Zhang FJ, Ma LL, Wang WN, Qian LB, Yang MJ, Yu J, Chen G, Yu LN, Yan M: Hypercholesterolemia abrogates sevoflurane-induced delayed preconditioning against myocardial infarct in rats by alteration of nitric oxide synthase signaling. Shock 37(5):485-491, 2012.
26. Yano T, Miki T, Tanno M, Kuno A, Itoh T, Takada A, Sato T, Kouzu H, Shimamoto K, Miura T: Hypertensive hypertrophied myocardium is vulnerable to infarction and refractory to erythropoietin-induced protection. Hypertension 57(1):110-115, 2011.
27. Dai W, Simkhovich BZ, Kloner RA: Ischemic preconditioning maintains cardioprotection in aging normotensive and spontaneously hypertensive rats. Exp Gerontol 44(5):344-349, 2009.
28. Hausenloy DJ, Yellon DM: Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 70(2):240-253, 2006.
29. Miura T, Miura T, Kawamura S, Goto M, Sakamoto J, Tsuchida A, Matsuzaki M, Shimamoto K: Effect of protein kinase C inhibitors on cardioprotection by ischemic preconditioning depends on the number of preconditioning episodes. Cardiovasc Res 37(3):700-709, 1998.
30. Raphael J, Abedat S, Rivo J, Meir K, Beeri R, Pugatsch T, Zuo Z, Gozal Y: Volatile anesthetic preconditioning attenuates myocardial apoptosis in rabbits after regional ischemia and reperfusion via Akt signaling and modulation of Bcl-2 family proteins. J Pharmacol Exp Ther 318(1):186-194, 2006.
31. Steenbergen C, Afshari CA, Petranka JG, Collins J, Martin K, Bennett L, Haugen A, Bushel P, Murphy E: Alterations in apoptotic signaling in human idiopathic cardiomyopathic hearts in failure. Am J Physiol Heart Circ Physiol 284(1):H268-H276, 2003.
32. Labat-Moleur F, Guillermet C, Lorimier P, Robert C, Lantuejoul S, Brambilla E, Negoescu A: TUNEL apoptotic cell detection in tissue sections: critical evaluation and improvement. J Histochem Cytochem 46(3):327-334, 1998.
33. Ding B, Price RL, Goldsmith EC, Borg TK, Yan X, Douglas PS, Weinberg EO, Bartunek J, Thielen T, Didenko VV, et al.: Left ventricular hypertrophy in ascending aortic stenosis mice: anoikis and the progression to early failure. Circulation 101(24):2854-2862, 2000.
34. Diamond JA, Phillips RA: Hypertensive heart disease. Hypertens Res 28(3): 191-202, 2005.